Search

Your search keyword '"Brown JR"' showing total 7,091 results
Start Over Author "Brown JR"

Refine your results

more »

more »

more »

more »

more »

more »

more »
7,091 results on '"Brown JR"'

3. Optimal management of ulnar collateral ligament injury in baseball pitchers

Author

Hibberd EE, Brown JR, and Hoffer JT

Subjects
Sports medicine, RC1200-1245
Abstract

Elizabeth E Hibberd,1 J Rodney Brown,2 Joseph T Hoffer21Department of Health Science, The University of Alabama, Tuscaloosa, AL, USA; 2Department of Intercollegiate Athletics, The University of Alabama, Tuscaloosa, AL, USAAbstract: The ulnar collateral ligament stabilizes the elbow joint from valgus stress associated with the throwing motion. During baseball pitching, this ligament is subjected to tremendous stress and injury if the force on the ulnar collateral ligament during pitching exceeds the physiological limits of the ligament. Injuries to the throwing elbow in baseball pitchers result in significant time loss and typically surgical intervention. The purpose of this paper is to provide a review of current information to sports medicine clinicians on injury epidemiology, injury mechanics, injury risk factors, injury prevention, surgical interventions, nonsurgical interventions, rehabilitation, and return to play outcomes in baseball pitchers of all levels.Keywords: ulnar collateral ligament, elbow injury, baseball, pitchers

Published
2015

6. B cell receptor pathway in chronic lymphocytic leukemia: specific role of CC-292

Author

Arnason JE and Brown JR

Subjects
Chronic lymphocytic lymphoma, B cell receptor, CC-292, Immunologic diseases. Allergy, RC581-607
Abstract

Jon E Arnason,1 Jennifer R Brown21Beth Israel Deaconess Medical Center, 2CLL Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USAAbstract: Chronic lymphocytic leukemia (CLL) is the most common adult leukemia. The current treatment paradigm involves the use of chemoimmunotherapy, when patients develop an indication for therapy. With this strategy, a majority of patients will obtain a remission, though cure remains elusive. While treatable, the majority of CLL patients will die of complications of their disease. Recent advances in the understanding of the importance of the B cell receptor (BCR) pathway in CLL have led to the development of a number of agents targeting this pathway. In this review, we discuss recent developments in the targeting of the BCR pathway, with a focus on CC-292. CC-292 covalently binds to Bruton's tyrosine kinase, a key mediator of BCR signaling, and has demonstrated preclinical and clinical activity in CLL, with acceptable tolerability. Based on the success of CC-292 and other inhibitors of the BCR pathway, these agents are being investigated in combination with standard therapy, with the hope that they will increase the depth and length of response, without significant toxicity.Keywords: Bruton's tyrosine kinase inhibitor, ibrutinib

Published
2014

7. Metabolic biomarkers for predicting cardiovascular disease

Author

Montgomery JE and Brown JR

Subjects
Diseases of the circulatory (Cardiovascular) system, RC666-701
Abstract

Jana E Montgomery,1,2 Jeremiah R Brown1–31Dartmouth-Hitchcock Medical Center, Division of Cardiology, Lebanon, NH, USA; 2Geisel School of Medicine, Hanover, NH, USA; 3The Dartmouth Institute for Health Policy and Clinical Practice, Lebanon, NH, USAAbstract: Cardiac and peripheral vascular biomarkers are increasingly becoming targets of both research and clinical practice. As of 2008, cardiovascular-related medical care accounts for greater than 20% of all the economic costs of illness in the United States. In the age of burgeoning financial pressures on the entire health care system, never has it been more important to try to understand who is at risk for cardiovascular disease in order to prevent new events. In this paper, we will discuss the cost of cardiovascular disease to society, clarify the definition of and need for biomarkers, offer an example of a current biomarker, namely high-sensitivity C-reactive protein, and finally examine the approval process for utilizing these in clinical practice.Keywords: cardiac biomarkers, cardiovascular disease

Published
2013

8. Identification of selective and non-selective C9ORF72 targeting in vivo active siRNAs

Author

James W. Gilbert, Zachary Kennedy, Bruno M.D.C. Godinho, Ashley Summers, Alexandra Weiss, Dimas Echeverria, Brianna Bramato, Nicholas McHugh, David Cooper, Ken Yamada, Matthew Hassler, Hélène Tran, Fen Biao Gao, Robert H. Brown, Jr., and Anastasia Khvorova

Subjects
MT: Oligonucleotides: Therapies and Applications, oligonucleotide therapeutics, siRNA, C9ORF72 amyotrophic lateral sclerosis, ALS, frontotemporal dementia, FTD, mRNA localization, Therapeutics. Pharmacology, RM1-950
Abstract

A hexanucleotide (G4C2) repeat expansion (HRE) within intron one of C9ORF72 is the leading genetic cause of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). C9ORF72 haploinsufficiency, formation of RNA foci, and production of dipeptide repeat (DPR) proteins have been proposed as mechanisms of disease. Here, we report the first example of disease-modifying siRNAs for C9ORF72 driven ALS/FTD. Using a combination of reporter assay and primary cortical neurons derived from a C9-ALS/FTD mouse model, we screened a panel of more than 150 fully chemically stabilized siRNAs targeting different C9ORF72 transcriptional variants. We demonstrate the lack of correlation between siRNA efficacy in reporter assay versus native environment; repeat-containing C9ORF72 mRNA variants are found to preferentially localize to the nucleus, and thus C9ORF72 mRNA accessibility and intracellular localization have a dominant impact on functional RNAi. Using a C9-ALS/FTD mouse model, we demonstrate that divalent siRNAs targeting C9ORF72 mRNA variants specifically or non-selectively reduce the expression of C9ORF72 mRNA and significantly reduce DPR proteins. Interestingly, siRNA silencing all C9ORF72 mRNA transcripts was more effective in removing intranuclear mRNA aggregates than targeting only HRE-containing C9ORF72 mRNA transcripts. Combined, these data support RNAi-based degradation of C9ORF72 as a potential therapeutic paradigm.

Published
2024
Full Text
View/download PDF

14. Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study

Author

Razavi-Shearer, Devin, Gamkrelidze, Ivane, Pan, Calvin, Jia, Jidong, Berg, Thomas, Gray, Richard, Lim, Young-Suk, Chen, Chien-Jen, Ocama, Ponsiano, Desalegn, Hailemichael, Abbas, Zaigham, Abdallah, Ayat, Aghemo, Alessio, Ahmadbekova, Sabohat, Ahn, Sang Hoon, Aho, Inka, Akarca, Ulus, Al Masri, Nasser, Alalwan, Abduljaleel, Alavian, Seyed, Al-Busafi, Said, Aleman, Soo, Alfaleh, Faleh, Alghamdi, Abdullah, Al-Hamoudi, Waleed, Aljumah, Abdulrahman, Al-Naamani, Khalid, Al-Rifai, Ahmad, Alserkal, Yousif, Altraif, Ibrahim, Amarsanaa, Jazag, Anderson, Motswedi, Andersson, Monique, Armstrong, Paige, Asselah, Tarik, Athanasakis, Kostas, Baatarkhuu, Oidov, Ben-Ari, Ziv, Bensalem, Aicha, Bessone, Fernando, Biondi, Mia, Bizri, Abdul Rahman, Blach, Sarah, Braga, Wornei, Brandão-Mello, Carlos, Brosgart, Carol, Brown, Kimberly, Brown, Jr, Robert, Bruggmann, Philip, Brunetto, Maurizia, Buti, Maria, Cabezas, Joaquin, Casanovas, Teresa, Chae, Chungman, Chan, Henry Lik Yuen, Cheinquer, Hugo, Chen, Pei-Jer, Cheng, Kent Jason, Cheon, Myeong-Eun, Chien, Cheng-Hung, Choudhuri, Gourdas, Christensen, Peer Brehm, Chuang, Wan-Long, Chulanov, Vladimir, Cisneros, Laura, Coffin, Carla, Contreras, Fernando, Coppola, Nicola, Cornberg, Markus, Cowie, Benjamin, Cramp, Matthew, Craxi, Antonio, Crespo, Javier, Cui, Fuqiang, Cunningham, Chris, Dalgard, Olav, De Knegt, Robert, De Ledinghen, Victor, Dore, Gregory, Drazilova, Sylvia, Duberg, Ann-Sofi, Egeonu, Steve, Elbadri, Mohammed, El-Kassas, Mohamed, El-Sayed, Manal, Estes, Chris, Etzion, Ohad, Farag, Elmobashar, Ferradini, Laurent, Ferreira, Paulo, Flisiak, Robert, Forns, Xavier, Frankova, Sona, Fung, James, Gane, Edward, Garcia, Virginia, García-Samaniego, Javier, Gemilyan, Manik, Genov, Jordan, Gheorghe, Liliana, Gholam, Pierre, Gish, Robert, Goleij, Pouya, Gottfredsson, Magnus, Grebely, Jason, Gschwantler, Michael, Guingane, Nanelin Alice, Hajarizadeh, Behzad, Hamid, Saeed, Hamoudi, Waseem, Harris, Aaron, Hasan, Irsan, Hatzakis, Angelos, Hellard, Margaret, Hercun, Julian, Hernandez, Javier, Hockicková, Ivana, Hsu, Yao-Chun, Hu, Ching-Chih, Husa, Petr, Janicko, Martin, Janjua, Naveed, Jarcuska, Peter, Jaroszewicz, Jerzy, Jelev, Deian, Jeruma, Agita, Johannessen, Asgeir, Kåberg, Martin, Kaita, Kelly, Kaliaskarova, Kulpash, Kao, Jia-Horng, Kelly-Hanku, Angela, Khamis, Faryal, Khan, Aamir, Kheir, Omer, Khoudri, Ibtissam, Kondili, Loreta, Konysbekova, Aliya, Kristian, Pavol, Kwon, Jisoo, Lagging, Martin, Laleman, Wim, Lampertico, Pietro, Lavanchy, Daniel, Lázaro, Pablo, Lazarus, Jeffrey V, Lee, Alice, Lee, Mei-Hsuan, Liakina, Valentina, Lukšić, Boris, Malekzadeh, Reza, Malu, Abraham, Marinho, Rui, Mendes-Correa, Maria Cássia, Merat, Shahin, Meshesha, Berhane Redae, Midgard, Håvard, Mohamed, Rosmawati, Mokhbat, Jacques, Mooneyhan, Ellen, Moreno, Christophe, Mortgat, Laure, Müllhaupt, Beat, Musabaev, Erkin, Muyldermans, Gaëtan, Naveira, Marcelo, Negro, Francesco, Nersesov, Alexander, Nguyen, Van Thi Thuy, Ning, Qing, Njouom, Richard, Ntagirabiri, Rénovat, Nurmatov, Zuridin, Oguche, Stephen, Omuemu, Casimir, Ong, Janus, Opare-Sem, Ohene, Örmeci, Necati, Orrego, Mauricio, Osiowy, Carla, Papatheodoridis, George, Peck-Radosavljevic, Markus, Pessoa, Mário, Pham, Trang, Phillips, Richard, Pimenov, Nikolay, Pincay-Rodríguez, Loreley, Plaseska-Karanfilska, Dijana, Pop, Cora, Poustchi, Hossein, Prabdial-Sing, Nishi, Qureshi, Huma, Ramji, Alnoor, Rautiainen, Henna, Razavi-Shearer, Kathryn, Remak, William, Ribeiro, Sofia, Ridruejo, Ezequiel, Ríos-Hincapié, Cielo, Robalino, Marcia, Roberts, Lewis, Roberts, Stuart, Rodríguez, Manuel, Roulot, Dominique, Rwegasha, John, Ryder, Stephen, Sadirova, Shakhlo, Saeed, Umar, Safadi, Rifaat, Sagalova, Olga, Said, Sanaa, Salupere, Riina, Sanai, Faisal, Sanchez-Avila, Juan F, Saraswat, Vivek, Sargsyants, Narina, Sarrazin, Christoph, Sarybayeva, Gulya, Schréter, Ivan, Seguin-Devaux, Carole, Seto, Wai-Kay, Shah, Samir, Sharara, Ala, Sheikh, Mahdi, Shouval, Daniel, Sievert, William, Simojoki, Kaarlo, Simonova, Marieta, Sinn, Dong Hyun, Sonderup, Mark, Sonneveld, Milan, Spearman, C Wendy, Sperl, Jan, Stauber, Rudolf, Stedman, Catherine, Sypsa, Vana, Tacke, Frank, Tan, Soek-Siam, Tanaka, Junko, Tergast, Tammo, Terrault, Norah, Thompson, Alexander, Thompson, Peyton, Tolmane, Ieva, Tomasiewicz, Krzysztof, Tsang, Tak-Yin, Uzochukwu, Benjamin, Van Welzen, Berend, Vanwolleghem, Thomas, Vince, Adriana, Voeller, Alexis, Waheed, Yasir, Waked, Imam, Wallace, Jack, Wang, Cong, Weis, Nina, Wong, Grace, Wong, Vincent, Wu, Jaw-Ching, Yaghi, Cesar, Yesmembetov, Kakharman, Yip, Terry, Yosry, Ayman, Yu, Ming-Lung, Yuen, Man-Fung, Yurdaydin, Cihan, Zeuzem, Stefan, Zuckerman, Eli, and Razavi, Homie

Published
2023
Full Text
View/download PDF

15. Experimental identification of the T=1, Jπ=6+ state of Co 54 and isospin symmetry in A=54 studied via one-nucleon knockout reactions

Author

Spieker, M, Weisshaar, D, Gade, A, Brown, BA, Adrich, P, Bazin, D, Bentley, MA, Brown, JR, Campbell, CM, Diget, CA, Elman, B, Glasmacher, T, Hill, M, Longfellow, B, Pritychenko, B, Ratkiewicz, A, Rhodes, D, and Tostevin, JA

Subjects
nucl-ex, nucl-th
Abstract

New experimental data obtained from γ-ray tagged one-neutron and one-proton knockout from Co55 are presented. A candidate for the sought-after T=1,Tz=0,Jπ=6+ state in Co54 is proposed based on a comparison to the new data on Fe54, the corresponding observables predicted by large-scale-shell-model (LSSM) calculations in the full fp-model space employing charge-dependent contributions, and isospin-symmetry arguments. Furthermore, possible isospin-symmetry breaking in the A=54, T=1 triplet is studied by calculating the experimental c coefficients of the isobaric mass multiplet equation (IMME) up to the maximum possible spin J=6 expected for the (1f7/2)-2 two-hole configuration relative to the doubly magic nucleus Ni56. The experimental quantities are compared to the theoretically predicted c coefficients from LSSM calculations using two-body matrix elements obtained from a realistic chiral effective field theory potential at next-to-next-to-next-to-leading order (N3LO).

Published
2019

16. Experimental identification of the T=1, Jπ=6+ state of Co54 and isospin symmetry in A=54 studied via one-nucleon knockout reactions

Author

Spieker, M, Weisshaar, D, Gade, A, Brown, BA, Adrich, P, Bazin, D, Bentley, MA, Brown, JR, Campbell, CM, Diget, C Aa, Elman, B, Glasmacher, T, Hill, M, Longfellow, B, Pritychenko, B, Ratkiewicz, A, Rhodes, D, and Tostevin, JA

Subjects
Nuclear and Plasma Physics, Synchrotrons and Accelerators, Physical Sciences, nucl-ex, nucl-th, Nuclear and plasma physics
Abstract

New experimental data obtained from γ-ray tagged one-neutron and one-proton knockout from Co55 are presented. A candidate for the sought-after T=1,Tz=0,Jπ=6+ state in Co54 is proposed based on a comparison to the new data on Fe54, the corresponding observables predicted by large-scale-shell-model (LSSM) calculations in the full fp-model space employing charge-dependent contributions, and isospin-symmetry arguments. Furthermore, possible isospin-symmetry breaking in the A=54, T=1 triplet is studied by calculating the experimental c coefficients of the isobaric mass multiplet equation (IMME) up to the maximum possible spin J=6 expected for the (1f7/2)-2 two-hole configuration relative to the doubly magic nucleus Ni56. The experimental quantities are compared to the theoretically predicted c coefficients from LSSM calculations using two-body matrix elements obtained from a realistic chiral effective field theory potential at next-to-next-to-next-to-leading order (N3LO).

Published
2019

17. One-proton and one-neutron knockout reactions from N=Z=28 Ni 56 to the A=55 mirror pair Co 55 and Ni 55

Author

Spieker, M, Gade, A, Weisshaar, D, Brown, BA, Tostevin, JA, Longfellow, B, Adrich, P, Bazin, D, Bentley, MA, Brown, JR, Campbell, CM, Diget, CA, Elman, B, Glasmacher, T, Hill, M, Pritychenko, B, Ratkiewicz, A, and Rhodes, D

Subjects
nucl-ex, nucl-th
Abstract

We present a high-resolution in-beam γ-ray spectroscopy study of excited states in the mirror nuclei Co55 and Ni55 following one-nucleon knockout from a projectile beam of Ni56. The newly determined partial cross sections and the γ-decay properties of excited states provide a test of state-of-the-art nuclear structure models and probe mirror symmetry in unique ways. The new experimental data are compared to large-scale shell-model calculations in the full pf space which include charge-dependent contributions. A mirror asymmetry for the partial cross sections leading to the two lowest 3/2- states in the A=55 mirror pair was identified as well as a significant difference in the E1 decays from the 1/21+ state to the same two 3/2- states. The mirror asymmetry in the partial cross sections cannot be reconciled with the present shell-model picture or small mixing introduced in a two-state model. The observed mirror asymmetry in the E1 decay pattern, however, points at stronger mixing between the two lowest 3/2- states in Co55 than in its mirror Ni55.

Published
2019

18. One-proton and one-neutron knockout reactions from N=Z=28Ni56 to the A=55 mirror pair Co55 and Ni55

Author

Spieker, M, Gade, A, Weisshaar, D, Brown, BA, Tostevin, JA, Longfellow, B, Adrich, P, Bazin, D, Bentley, MA, Brown, JR, Campbell, CM, Diget, C Aa, Elman, B, Glasmacher, T, Hill, M, Pritychenko, B, Ratkiewicz, A, and Rhodes, D

Subjects
Nuclear and Plasma Physics, Synchrotrons and Accelerators, Physical Sciences, nucl-ex, nucl-th, Nuclear and plasma physics
Abstract

We present a high-resolution in-beam γ-ray spectroscopy study of excited states in the mirror nuclei Co55 and Ni55 following one-nucleon knockout from a projectile beam of Ni56. The newly determined partial cross sections and the γ-decay properties of excited states provide a test of state-of-the-art nuclear structure models and probe mirror symmetry in unique ways. The new experimental data are compared to large-scale shell-model calculations in the full pf space which include charge-dependent contributions. A mirror asymmetry for the partial cross sections leading to the two lowest 3/2- states in the A=55 mirror pair was identified as well as a significant difference in the E1 decays from the 1/21+ state to the same two 3/2- states. The mirror asymmetry in the partial cross sections cannot be reconciled with the present shell-model picture or small mixing introduced in a two-state model. The observed mirror asymmetry in the E1 decay pattern, however, points at stronger mixing between the two lowest 3/2- states in Co55 than in its mirror Ni55.

Published
2019

19. Rescue of GM3 synthase deficiency by spatially controlled, rAAV-mediated ST3GAL5 delivery

Author

Huiya Yang, Robert H. Brown Jr., Dan Wang, Kevin A. Strauss, and Guangping Gao

Subjects
Neuroscience, Therapeutics, Medicine
Abstract

GM3 synthase deficiency (GM3SD) is an infantile-onset epileptic encephalopathy syndrome caused by biallelic loss-of-function mutations in ST3GAL5. Loss of ST3GAL5 activity in humans results in systemic ganglioside deficiency and severe neurological impairment. No disease-modifying treatment is currently available. Certain recombinant adeno-associated viruses (rAAVs) can cross the blood-brain barrier to induce widespread, long-term gene expression in the CNS and represent a promising therapeutic strategy. Here, we show that a first-generation rAAV-ST3GAL5 replacement vector using a ubiquitous promoter restored tissue ST3GAL5 expression and normalized cerebral gangliosides in patient-derived induced pluripotent stem cell neurons and brain tissue from St3gal5-KO mice but caused fatal hepatotoxicity when administered systemically. In contrast, a second-generation vector optimized for CNS-restricted ST3GAL5 expression, administered by either the intracerebroventricular or i.v. route at P1, allowed for safe and effective rescue of lethality and behavior impairment in symptomatic GM3SD mice up to a year. These results support further clinical development of ST3GAL5 gene therapy.

Published
2023
Full Text
View/download PDF

20. Whole-genome sequencing reveals that variants in the Interleukin 18 Receptor Accessory Protein 3′UTR protect against ALS

Author

Eitan, Chen, Siany, Aviad, Barkan, Elad, Olender, Tsviya, van Eijk, Kristel R., Moisse, Matthieu, Farhan, Sali M. K., Danino, Yehuda M., Yanowski, Eran, Marmor-Kollet, Hagai, Rivkin, Natalia, Yacovzada, Nancy Sarah, Hung, Shu-Ting, Cooper-Knock, Johnathan, Yu, Chien-Hsiung, Louis, Cynthia, Masters, Seth L., Kenna, Kevin P., van der Spek, Rick A. A., Sproviero, William, Al Khleifat, Ahmad, Iacoangeli, Alfredo, Shatunov, Aleksey, Jones, Ashley R., Elbaz-Alon, Yael, Cohen, Yahel, Chapnik, Elik, Rothschild, Daphna, Weissbrod, Omer, Beck, Gilad, Ainbinder, Elena, Ben-Dor, Shifra, Werneburg, Sebastian, Schafer, Dorothy P., Brown, Jr, Robert H., Shaw, Pamela J., Van Damme, Philip, van den Berg, Leonard H., Phatnani, Hemali, Segal, Eran, Ichida, Justin K., Al-Chalabi, Ammar, Veldink, Jan H., and Hornstein, Eran

Published
2022
Full Text
View/download PDF

22. Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study

Author

Blach, Sarah, Terrault, Norah A, Tacke, Frank, Gamkrelidze, Ivane, Craxi, Antonio, Tanaka, Junko, Waked, Imam, Dore, Gregory J, Abbas, Zaigham, Abdallah, Ayat R, Abdulla, Maheeba, Aghemo, Alessio, Aho, Inka, Akarca, Ulus S, Alalwan, Abduljaleel M, Alanko Blomé, Marianne, Al-Busafi, Said A, Aleman, Soo, Alghamdi, Abdullah S, Al-Hamoudi, Waleed K, Aljumah, Abdulrahman A, Al-Naamani, Khalid, Al Serkal, Yousif M, Altraif, Ibrahim H, Anand, Anil C, Anderson, Motswedi, Andersson, Monique I, Athanasakis, Kostas, Baatarkhuu, Oidov, Bakieva, Shokhista R, Ben-Ari, Ziv, Bessone, Fernando, Biondi, Mia J, Bizri, Abdul Rahman N, Brandão-Mello, Carlos E, Brigida, Krestina, Brown, Kimberly A, Brown, Jr, Robert S, Bruggmann, Philip, Brunetto, Maurizia R, Busschots, Dana, Buti, Maria, Butsashvili, Maia, Cabezas, Joaquin, Chae, Chungman, Chaloska Ivanova, Viktorija, Chan, Henry Lik Yuen, Cheinquer, Hugo, Cheng, Kent Jason, Cheon, Myeong-Eun, Chien, Cheng-Hung, Chien, Rong-Nan, Choudhuri, Gourdas, Christensen, Peer Brehm, Chuang, Wan-Long, Chulanov, Vladimir, Cisneros, Laura E, Coco, Barbara, Contreras, Fernando A, Cornberg, Markus, Cramp, Matthew E, Crespo, Javier, Cui, Fuqiang, Cunningham, Chris W, Dagher Abou, Lucy, Dalgard, Olav, Dao, Doan Y, De Ledinghen, Victor, Derbala, Moutaz F, Deuba, Keshab, Dhindsa, Karan, Djauzi, Samsuridjal, Drazilova, Sylvia, Duberg, Ann-Sofi, Elbadri, Mohammed, El-Sayed, Manal H, Esmat, Gamal, Estes, Chris, Ezzat, Sameera, Färkkilä, Martti A, Ferradini, Laurent, Ferraz, Maria Lucia G, Ferreira, Paulo R A, Filipec Kanizaj, Tajana, Flisiak, Robert, Frankova, Sona, Fung, James, Gamkrelidze, Amiran, Gane, Edward, Garcia, Virginia, García-Samaniego, Javier, Gemilyan, Manik, Genov, Jordan, Gheorghe, Liliana S, Gholam, Pierre M, Goldis, Adrian, Gottfredsson, Magnus, Gray, Richard T, Grebely, Jason, Gschwantler, Michael, Hajarizadeh, Behzad, Hamid, Saeed S, Hamoudi, Waseem, Hatzakis, Angelos, Hellard, Margaret E, Himatt, Sayed, Hofer, Harald, Hrstic, Irena, Hunyady, Bela, Husa, Petr, Husic-Selimovic, Azra, Jafri, Wasim S M, Janicko, Martin, Janjua, Naveed, Jarcuska, Peter, Jaroszewicz, Jerzy, Jerkeman, Anna, Jeruma, Agita, Jia, Jidong, Jonasson, Jon G, Kåberg, Martin, Kaita, Kelly D E, Kaliaskarova, Kulpash S, Kao, Jia-Horng, Kasymov, Omor T, Kelly-Hanku, Angela, Khamis, Faryal, Khamis, Jawad, Khan, Aamir G, Khandu, Lekey, Khoudri, Ibtissam, Kielland, Knut B, Kim, Do Young, Kodjoh, Nicolas, Kondili, Loreta A, Krajden, Mel, Krarup, Henrik Bygum, Kristian, Pavol, Kwon, Jisoo A, Lagging, Martin, Laleman, Wim, Lao, Wai Cheung, Lavanchy, Daniel, Lázaro, Pablo, Lazarus, Jeffrey V, Lee, Alice U, Lee, Mei-Hsuan, Li, Michael K K, Liakina, Valentina, Lim, Young-Suk, Löve, Arthur, Lukšić, Boris, Machekera, Shepherd Mufudzi, Malu, Abraham O, Marinho, Rui T, Maticic, Mojca, Mekonnen, Hailemichael D, Mendes-Correa, Maria Cássia, Mendez-Sanchez, Nahum, Merat, Shahin, Meshesha, Berhane Redae, Midgard, Håvard, Mills, Mike, Mohamed, Rosmawati, Mooneyhan, Ellen, Moreno, Christophe, Muljono, David H, Müllhaupt, Beat, Musabaev, Erkin, Muyldermans, Gaëtan, Nartey, Yvonne Ayerki, Naveira, Marcelo C M, Negro, Francesco, Nersesov, Alexander V, Njouom, Richard, Ntagirabiri, Rénovat, Nurmatov, Zuridin S, Obekpa, Solomon A, Oguche, Stephen, Olafsson, Sigurdur, Ong, Janus P, Opare-Sem, Ohene K, Orrego, Mauricio, Øvrehus, Anne L, Pan, Calvin Q, Papatheodoridis, George V, Peck-Radosavljevic, Markus, Pessoa, Mário G, Phillips, Richard O, Pimenov, Nikolay, Plaseska-Karanfilska, Dijana, Prabdial-Sing, Nishi N, Puri, Pankaj, Qureshi, Huma, Rahman, Aninda, Ramji, Alnoor, Razavi-Shearer, Devin M, Razavi-Shearer, Kathryn, Ridruejo, Ezequiel, Ríos-Hincapié, Cielo Y, Rizvi, S M Shahriar, Robaeys, Geert K M M, Roberts, Lewis R, Roberts, Stuart K, Ryder, Stephen D, Sadirova, Shakhlo, Saeed, Umar, Safadi, Rifaat, Sagalova, Olga, Said, Sanaa S, Salupere, Riina, Sanai, Faisal M, Sanchez-Avila, Juan F, Saraswat, Vivek A, Sarrazin, Christoph, Sarybayeva, Gulya, Seguin-Devaux, Carole, Sharara, Ala I, Sheikh, Mahdi, Shewaye, Abate B, Sievert, William, Simojoki, Kaarlo, Simonova, Marieta Y, Sonderup, Mark W, Spearman, C Wendy, Sperl, Jan, Stauber, Rudolf E, Stedman, Catherine A M, Su, Tung-Hung, Suleiman, Anita, Sypsa, Vana, Tamayo Antabak, Natalia, Tan, Soek-Siam, Tergast, Tammo L, Thurairajah, Prem H, Tolmane, Ieva, Tomasiewicz, Krzysztof, Tsereteli, Maia, Uzochukwu, Benjamin S C, Van De Vijver, David A M C, Van Santen, Daniela K, Van Vlierberghe, Hans, Van Welzen, Berend, Vanwolleghem, Thomas, Vélez-Möller, Patricia, Villamil, Federico, Vince, Adriana, Waheed, Yasir, Weis, Nina, Wong, Vincent W-S, Yaghi, Cesar G, Yesmembetov, Kakharman, Yosry, Ayman, Yuen, Man-Fung, Yunihastuti, Evy, Zeuzem, Stefan, Zuckerman, Eli, and Razavi, Homie A

Published
2022
Full Text
View/download PDF

25. AAV gene therapy for Tay-Sachs disease

Author

Flotte, Terence R., Cataltepe, Oguz, Puri, Ajit, Batista, Ana Rita, Moser, Richard, McKenna-Yasek, Diane, Douthwright, Catherine, Gernoux, Gwladys, Blackwood, Meghan, Mueller, Christian, Tai, Phillip W. L., Jiang, Xuntian, Bateman, Scot, Spanakis, Spiro G., Parzych, Julia, Keeler, Allison M., Abayazeed, Aly, Rohatgi, Saurabh, Gibson, Laura, Finberg, Robert, Barton, Bruce A., Vardar, Zeynep, Shazeeb, Mohammed Salman, Gounis, Matthew, Tifft, Cynthia J., Eichler, Florian S., Brown, Jr., Robert H., Martin, Douglas R., Gray-Edwards, Heather L., and Sena-Esteves, Miguel

Published
2022
Full Text
View/download PDF

26. Suppression of mutant C9orf72 expression by a potent mixed backbone antisense oligonucleotide

Author

Tran, Hélène, Moazami, Michael P., Yang, Huiya, McKenna-Yasek, Diane, Douthwright, Catherine L., Pinto, Courtney, Metterville, Jake, Shin, Minwook, Sanil, Nitasha, Dooley, Craig, Puri, Ajit, Weiss, Alexandra, Wightman, Nicholas, Gray-Edwards, Heather, Marosfoi, Miklos, King, Robert M., Kenderdine, Thomas, Fabris, Daniele, Bowser, Robert, Watts, Jonathan K., and Brown, Jr, Robert H.

Published
2022
Full Text
View/download PDF

27. Evaluating sleep in covert encephalopathy with wearable technology: results from the WATCHES study

Author

Adam Buckholz, Lindsay Clarke, Paul Paik, Arun Jesudian, Robert Schwartz, Ana Krieger, Russell Rosenblatt, and Robert S. Brown, Jr

Subjects
Diseases of the digestive system. Gastroenterology, RC799-869
Abstract

Background and Aims:. Covert HE (CHE) is a common early stage of HE associated with poor outcomes. Available neuropsychiatric diagnostic testing is underutilized and has significant clinical limitations. Sleep deterioration is consistently associated with CHE and HE; however, objective data is sparse and it has not been studied longitudinally. We longitudinally study and describe an association of sleep metrics with CHE as detected by a commercial wearable technology. Methods:. We monitored sleep for 6 months using a commercial fitness tracker in 25 participants with cirrhosis, hypothesizing that CHE as diagnosed by psychometric testing would be associated with significant reductions in sleep quality, especially restorative sleep (deep sleep + rapid eye movement). Mixed-effects modeling was performed to evaluate sleep factors associated with CHE and developed and internally validated a score based on these sleep metrics for associated CHE. Results:. Across 2862 nights with 66.3% study adherence, we found that those with CHE had consistently worse sleep, including an average of 1 hour less of nightly restorative sleep, driven primarily by reductions in rapid eye movement. A model including albumin, bilirubin, rapid eye movement, sleep disturbances, and sleep consistency showed good discrimination (area under the receiver operating curve=0.79) for CHE status with a sensitivity of 76% and specificity of 69%. Conclusions:. Our large longitudinal study of sleep in cirrhosis suggests that sleep derangements in CHE can be detected using wearable technology. Given the known importance of sleep to overall health and CHE/HE to prognosis in cirrhosis, the ability to associate dynamic sleep metrics with CHE may in the future help with the detection and passive monitoring as factors that precipitate decompensation of cirrhosis become better understood and mobile health data validation and integration improves.

Published
2023
Full Text
View/download PDF

28. Common and rare variant association analyses in amyotrophic lateral sclerosis identify 15 risk loci with distinct genetic architectures and neuron-specific biology

Author

van Rheenen, Wouter, van der Spek, Rick A. A., Bakker, Mark K., van Vugt, Joke J. F. A., Hop, Paul J., Zwamborn, Ramona A. J., de Klein, Niek, Westra, Harm-Jan, Bakker, Olivier B., Deelen, Patrick, Shireby, Gemma, Hannon, Eilis, Moisse, Matthieu, Baird, Denis, Restuadi, Restuadi, Dolzhenko, Egor, Dekker, Annelot M., Gawor, Klara, Westeneng, Henk-Jan, Tazelaar, Gijs H. P., van Eijk, Kristel R., Kooyman, Maarten, Byrne, Ross P., Doherty, Mark, Heverin, Mark, Al Khleifat, Ahmad, Iacoangeli, Alfredo, Shatunov, Aleksey, Ticozzi, Nicola, Cooper-Knock, Johnathan, Smith, Bradley N., Gromicho, Marta, Chandran, Siddharthan, Pal, Suvankar, Morrison, Karen E., Shaw, Pamela J., Hardy, John, Orrell, Richard W., Sendtner, Michael, Meyer, Thomas, Başak, Nazli, van der Kooi, Anneke J., Ratti, Antonia, Fogh, Isabella, Gellera, Cinzia, Lauria, Giuseppe, Corti, Stefania, Cereda, Cristina, Sproviero, Daisy, D’Alfonso, Sandra, Sorarù, Gianni, Siciliano, Gabriele, Filosto, Massimiliano, Padovani, Alessandro, Chiò, Adriano, Calvo, Andrea, Moglia, Cristina, Brunetti, Maura, Canosa, Antonio, Grassano, Maurizio, Beghi, Ettore, Pupillo, Elisabetta, Logroscino, Giancarlo, Nefussy, Beatrice, Osmanovic, Alma, Nordin, Angelica, Lerner, Yossef, Zabari, Michal, Gotkine, Marc, Baloh, Robert H., Bell, Shaughn, Vourc’h, Patrick, Corcia, Philippe, Couratier, Philippe, Millecamps, Stéphanie, Meininger, Vincent, Salachas, François, Mora Pardina, Jesus S., Assialioui, Abdelilah, Rojas-García, Ricardo, Dion, Patrick A., Ross, Jay P., Ludolph, Albert C., Weishaupt, Jochen H., Brenner, David, Freischmidt, Axel, Bensimon, Gilbert, Brice, Alexis, Durr, Alexandra, Payan, Christine A. M., Saker-Delye, Safa, Wood, Nicholas W., Topp, Simon, Rademakers, Rosa, Tittmann, Lukas, Lieb, Wolfgang, Franke, Andre, Ripke, Stephan, Braun, Alice, Kraft, Julia, Whiteman, David C., Olsen, Catherine M., Uitterlinden, Andre G., Hofman, Albert, Rietschel, Marcella, Cichon, Sven, Nöthen, Markus M., Amouyel, Philippe, Traynor, Bryan J., Singleton, Andrew B., Mitne Neto, Miguel, Cauchi, Ruben J., Ophoff, Roel A., Wiedau-Pazos, Martina, Lomen-Hoerth, Catherine, van Deerlin, Vivianna M., Grosskreutz, Julian, Roediger, Annekathrin, Gaur, Nayana, Jörk, Alexander, Barthel, Tabea, Theele, Erik, Ilse, Benjamin, Stubendorff, Beatrice, Witte, Otto W., Steinbach, Robert, Hübner, Christian A., Graff, Caroline, Brylev, Lev, Fominykh, Vera, Demeshonok, Vera, Ataulina, Anastasia, Rogelj, Boris, Koritnik, Blaž, Zidar, Janez, Ravnik-Glavač, Metka, Glavač, Damjan, Stević, Zorica, Drory, Vivian, Povedano, Monica, Blair, Ian P., Kiernan, Matthew C., Benyamin, Beben, Henderson, Robert D., Furlong, Sarah, Mathers, Susan, McCombe, Pamela A., Needham, Merrilee, Ngo, Shyuan T., Nicholson, Garth A., Pamphlett, Roger, Rowe, Dominic B., Steyn, Frederik J., Williams, Kelly L., Mather, Karen A., Sachdev, Perminder S., Henders, Anjali K., Wallace, Leanne, de Carvalho, Mamede, Pinto, Susana, Petri, Susanne, Weber, Markus, Rouleau, Guy A., Silani, Vincenzo, Curtis, Charles J., Breen, Gerome, Glass, Jonathan D., Brown, Jr., Robert H., Landers, John E., Shaw, Christopher E., Andersen, Peter M., Groen, Ewout J. N., van Es, Michael A., Pasterkamp, R. Jeroen, Fan, Dongsheng, Garton, Fleur C., McRae, Allan F., Davey Smith, George, Gaunt, Tom R., Eberle, Michael A., Mill, Jonathan, McLaughlin, Russell L., Hardiman, Orla, Kenna, Kevin P., Wray, Naomi R., Tsai, Ellen, Runz, Heiko, Franke, Lude, Al-Chalabi, Ammar, Van Damme, Philip, van den Berg, Leonard H., and Veldink, Jan H.

Published
2021
Full Text
View/download PDF

31. Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL

Author

Brown, JR, Hillmen, P, O’Brien, S, Barrientos, JC, Reddy, NM, Coutre, SE, Tam, CS, Mulligan, SP, Jaeger, U, Barr, PM, Furman, RR, Kipps, TJ, Cymbalista, F, Thornton, P, Caligaris-Cappio, F, Delgado, J, Montillo, M, DeVos, S, Moreno, C, Pagel, JM, Munir, T, Burger, JA, Chung, D, Lin, J, Gau, L, Chang, B, Cole, G, Hsu, E, James, DF, and Byrd, JC

Subjects
Rare Diseases, Clinical Research, Lymphoma, Genetics, Cancer, Hematology, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Adenine, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Disease-Free Survival, Female, Follow-Up Studies, Humans, Leukemia, Lymphocytic, Chronic, B-Cell, Male, Middle Aged, Mutation, Neoplasm Recurrence, Local, Piperidines, Prognosis, Pyrazoles, Pyrimidines, Tumor Suppressor Protein p53, Clinical Sciences, Oncology and Carcinogenesis, Immunology
Abstract

In the phase 3 RESONATE study, ibrutinib demonstrated superior progression-free survival (PFS), overall survival (OS) and overall response rate (ORR) compared with ofatumumab in relapsed/refractory CLL patients with high-risk prognostic factors. We report updated results from RESONATE in these traditionally chemotherapy resistant high-risk genomic subgroups at a median follow-up of 19 months. Mutations were detected by Foundation One Heme Panel. Baseline mutations in the ibrutinib arm included TP53 (51%), SF3B1 (31%), NOTCH1 (28%), ATM (19%) and BIRC3 (14%). Median PFS was not reached, with 74% of patients randomized to ibrutinib alive and progression-free at 24 months. The improved efficacy of ibrutinib vs ofatumumab continues in all prognostic subgroups including del17p and del11q. No significant difference within the ibrutinib arm was observed for PFS across most genomic subtypes, although a subset carrying both TP53 mutation and del17p had reduced PFS compared with patients with neither abnormality. Reduced PFS or OS was not evident in patients with only del17p. PFS was significantly better for ibrutinib-treated patients in second-line vs later lines of therapy. The robust clinical activity of ibrutinib continues to show ongoing efficacy and acceptable safety consistent with prior reports, independent of various known high-risk mutations.

Published
2018

33. Leukemia-cell proliferation and disease progression in patients with early stage chronic lymphocytic leukemia

Author

Murphy, EJ, Neuberg, DS, Rassenti, LZ, Hayes, G, Redd, R, Emson, C, Li, K, Brown, JR, Wierda, WG, Turner, S, Greaves, AW, Zent, CS, Byrd, JC, McConnel, C, Barrientos, J, Kay, N, Hellerstein, MK, Chiorazzi, N, Kipps, TJ, and Rai, KR

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Prevention, Hematology, Cancer, Lymphoma, Rare Diseases, Clinical Research, Adult, Aged, Aged, 80 and over, Biomarkers, Tumor, Cell Proliferation, Disease Progression, Female, Follow-Up Studies, Humans, Leukemia, Lymphocytic, Chronic, B-Cell, Male, Middle Aged, Mutation, Neoplasm Staging, Prognosis, Prospective Studies, Survival Rate, Clinical Sciences, Immunology, Cardiovascular medicine and haematology, Clinical sciences, Oncology and carcinogenesis
Abstract

The clinical course of patients with recently diagnosed early stage chronic lymphocytic leukemia (CLL) is highly variable. We examined the relationship between CLL-cell birth rate and treatment-free survival (TFS) in 97 patients with recently diagnosed, Rai stage 0-II CLL in a blinded, prospective study, using in vivo 2H2O labeling. Birth rates ranged from 0.07 to 1.31% new cells per day. With median follow-up of 4.0 years, 33 subjects (34%) required treatment by NCI criteria. High-birth rate was observed in 44% of subjects and was significantly associated with shorter TFS, unmutated IGHV status and expression of ZAP70 and of CD38. In multivariable modeling considering age, gender, Rai stage, expression of ZAP70 or CD38, IGHV mutation status and FISH cytogenetics, only CLL-cell birth rate and IGHV mutation status met criteria for inclusion. Hazard ratios were 3.51 (P=0.002) for high-birth rate and 4.93 (P

Published
2017

34. Ibrutinib in previously treated chronic lymphocytic leukemia patients with autoimmune cytopenias in the RESONATE study

Author

Montillo, M, O'Brien, S, Tedeschi, A, Byrd, JC, Dearden, C, Gill, D, Brown, JR, Barrientos, JC, Mulligan, SP, Furman, RR, Cymbalista, F, Plascencia, C, Chang, S, Hsu, E, James, DF, and Hillmen, P

Subjects
Biomedical and Clinical Sciences, Immunology, Adenine, Anemia, Hemolytic, Autoimmune, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Clinical Trials, Phase III as Topic, Humans, Leukemia, Lymphocytic, Chronic, B-Cell, Piperidines, Purpura, Thrombocytopenic, Idiopathic, Pyrazoles, Pyrimidines, Randomized Controlled Trials as Topic, Retrospective Studies, Treatment Outcome, Cardiorespiratory Medicine and Haematology, Oncology and Carcinogenesis, Cardiovascular medicine and haematology, Oncology and carcinogenesis
Published
2017

35. Elevated Southern Hemisphere moisture availability during glacial periods

Author

Weij, R, Sniderman, JMK, Woodhead, JD, Hellstrom, JC, Brown, JR, Drysdale, RN, Reed, E, Bourne, S, Gordon, J, Weij, R, Sniderman, JMK, Woodhead, JD, Hellstrom, JC, Brown, JR, Drysdale, RN, Reed, E, Bourne, S, and Gordon, J

Abstract

Late Pleistocene ice-age climates are routinely characterized as having imposed moisture stress on low- to mid-latitude ecosystems1-5. This idea is largely based on fossil pollen evidence for widespread, low-biomass glacial vegetation, interpreted as indicating climatic dryness6. However, woody plant growth is inhibited under low atmospheric CO2 (refs. 7,8), so understanding glacial environments requires the development of new palaeoclimate indicators that are independent of vegetation9. Here we show that, contrary to expectations, during the past 350 kyr, peaks in southern Australian climatic moisture availability were largely confined to glacial periods, including the Last Glacial Maximum, whereas warm interglacials were relatively dry. By measuring the timing of speleothem growth in the Southern Hemisphere subtropics, which today has a predominantly negative annual moisture balance, we developed a record of climatic moisture availability that is independent of vegetation and extends through multiple glacial-interglacial cycles. Our results demonstrate that a cool-moist response is consistent across the austral subtropics and, in part, may result from reduced evaporation under cool glacial temperatures. Insofar as cold glacial environments in the Southern Hemisphere subtropics have been portrayed as uniformly arid3,10,11, our findings suggest that their characterization as evolutionary or physiological obstacles to movement and expansion of animal, plant and, potentially, human populations10 should be reconsidered.

Published
2024

37. Relationship between updated MELD and prognosis in alcohol-associated hepatitis: Opportunities for more efficient trial design.

Author

Al-Karaghouli, Mustafa, Ventura-Cots, Meritxell, Wong, Yu Jun, Genesca, Joan, Bosques, Francisco, Brown Jr, Robert S., Mathurin, Philippe, Louvet, Alexandre, Shawcross, Debbie, Vargas, Victor, Verna, Elizabeth C., Schnabl, Bernd, Caballeria, Joan, Shah, Vijay J., Kamath, Patrick S., Lucey, Michael R., Garcia-Tsao, Guadalupe, Bataller, Ramon, and Abraldes, Juan G.

Published
2024
Full Text
View/download PDF

40. The Met Opera Puts On a Malcolm X Marathon

Author

Ugwu, Reggie and Brown Jr., Elliott Jerome

Subjects
Dramatists, News, opinion and commentary
Abstract

For 18 hours on a rainy Sunday this Halloween weekend, the Metropolitan Opera House was visited by the ghost of Malcolm X. Words made famous by the Black nationalist leader [...]

Published
2023

41. The Chairman on Trust.

Author

Brown Jr., C. Q.

Subjects
*COMMAND of troops, *PROFESSIONALISM, *PUBLIC support, *MILITARY discipline
Abstract

The article focuses on the essential role of trust in military leadership and its importance in maintaining professionalism and public confidence. Topics include the historical perspective on trust provided by General George Marshall, the critical need for maintaining nonpartisan integrity in military conduct, and the necessity of trust within military ranks, relationships, and public perception.

Published
2024

42. Why imaging is key to managing geographic atrophy: Paying attention to high-resolution OCT is more important than ever.

Author

Brown Jr, Jeremiah

Subjects
*CLINICAL drug trials, *ATROPHY
Abstract

The article discusses the importance of using high-resolution optical coherence tomography (OCT) imaging to manage geographic atrophy (GA) in patients with age-related macular degeneration (AMD). The author emphasizes the need for eye care providers to closely monitor patients with early signs of GA and educate them about new treatment options. The article also highlights the use of OCT imaging to identify atrophy and outlines the three groups of patients who should be monitored for GA progression. Additionally, the article mentions the possibility of developing wet AMD and the importance of regular OCT examinations to catch and treat it early. The author encourages a positive attitude and emphasizes the importance of lifestyle behaviors and diet in managing GA. Overall, the article emphasizes the significance of imaging and prompt follow-up in the management of GA. [Extracted from the article]

Published
2024

48. Author Correction: Common and rare variant association analyses in amyotrophic lateral sclerosis identify 15 risk loci with distinct genetic architectures and neuron-specific biology

Author

van Rheenen, Wouter, van der Spek, Rick A. A., Bakker, Mark K., van Vugt, Joke J. F. A., Hop, Paul J., Zwamborn, Ramona A. J., de Klein, Niek, Westra, Harm-Jan, Bakker, Olivier B., Deelen, Patrick, Shireby, Gemma, Hannon, Eilis, Moisse, Matthieu, Baird, Denis, Restuadi, Restuadi, Dolzhenko, Egor, Dekker, Annelot M., Gawor, Klara, Westeneng, Henk-Jan, Tazelaar, Gijs H. P., van Eijk, Kristel R., Kooyman, Maarten, Byrne, Ross P., Doherty, Mark, Heverin, Mark, Al Khleifat, Ahmad, Iacoangeli, Alfredo, Shatunov, Aleksey, Ticozzi, Nicola, Cooper-Knock, Johnathan, Smith, Bradley N., Gromicho, Marta, Chandran, Siddharthan, Pal, Suvankar, Morrison, Karen E., Shaw, Pamela J., Hardy, John, Orrell, Richard W., Sendtner, Michael, Meyer, Thomas, Başak, Nazli, van der Kooi, Anneke J., Ratti, Antonia, Fogh, Isabella, Gellera, Cinzia, Lauria, Giuseppe, Corti, Stefania, Cereda, Cristina, Sproviero, Daisy, D’Alfonso, Sandra, Sorarù, Gianni, Siciliano, Gabriele, Filosto, Massimiliano, Padovani, Alessandro, Chiò, Adriano, Calvo, Andrea, Moglia, Cristina, Brunetti, Maura, Canosa, Antonio, Grassano, Maurizio, Beghi, Ettore, Pupillo, Elisabetta, Logroscino, Giancarlo, Nefussy, Beatrice, Osmanovic, Alma, Nordin, Angelica, Lerner, Yossef, Zabari, Michal, Gotkine, Marc, Baloh, Robert H., Bell, Shaughn, Vourc’h, Patrick, Corcia, Philippe, Couratier, Philippe, Millecamps, Stéphanie, Meininger, Vincent, Salachas, François, Mora Pardina, Jesus S., Assialioui, Abdelilah, Rojas-García, Ricardo, Dion, Patrick A., Ross, Jay P., Ludolph, Albert C., Weishaupt, Jochen H., Brenner, David, Freischmidt, Axel, Bensimon, Gilbert, Brice, Alexis, Durr, Alexandra, Payan, Christine A. M., Saker-Delye, Safa, Wood, Nicholas W., Topp, Simon, Rademakers, Rosa, Tittmann, Lukas, Lieb, Wolfgang, Franke, Andre, Ripke, Stephan, Braun, Alice, Kraft, Julia, Whiteman, David C., Olsen, Catherine M., Uitterlinden, Andre G., Hofman, Albert, Rietschel, Marcella, Cichon, Sven, Nöthen, Markus M., Amouyel, Philippe, Traynor, Bryan J., Singleton, Andrew B., Mitne Neto, Miguel, Cauchi, Ruben J., Ophoff, Roel A., Wiedau-Pazos, Martina, Lomen-Hoerth, Catherine, van Deerlin, Vivianna M., Grosskreutz, Julian, Roediger, Annekathrin, Gaur, Nayana, Jörk, Alexander, Barthel, Tabea, Theele, Erik, Ilse, Benjamin, Stubendorff, Beatrice, Witte, Otto W., Steinbach, Robert, Hübner, Christian A., Graff, Caroline, Brylev, Lev, Fominykh, Vera, Demeshonok, Vera, Ataulina, Anastasia, Rogelj, Boris, Koritnik, Blaž, Zidar, Janez, Ravnik-Glavač, Metka, Glavač, Damjan, Stević, Zorica, Drory, Vivian, Povedano, Monica, Blair, Ian P., Kiernan, Matthew C., Benyamin, Beben, Henderson, Robert D., Furlong, Sarah, Mathers, Susan, McCombe, Pamela A., Needham, Merrilee, Ngo, Shyuan T., Nicholson, Garth A., Pamphlett, Roger, Rowe, Dominic B., Steyn, Frederik J., Williams, Kelly L., Mather, Karen A., Sachdev, Perminder S., Henders, Anjali K., Wallace, Leanne, de Carvalho, Mamede, Pinto, Susana, Petri, Susanne, Weber, Markus, Rouleau, Guy A., Silani, Vincenzo, Curtis, Charles J., Breen, Gerome, Glass, Jonathan D., Brown, Jr., Robert H., Landers, John E., Shaw, Christopher E., Andersen, Peter M., Groen, Ewout J. N., van Es, Michael A., Pasterkamp, R. Jeroen, Fan, Dongsheng, Garton, Fleur C., McRae, Allan F., Davey Smith, George, Gaunt, Tom R., Eberle, Michael A., Mill, Jonathan, McLaughlin, Russell L., Hardiman, Orla, Kenna, Kevin P., Wray, Naomi R., Tsai, Ellen, Runz, Heiko, Franke, Lude, Al-Chalabi, Ammar, Van Damme, Philip, van den Berg, Leonard H., and Veldink, Jan H.

Published
2022
Full Text
View/download PDF

49. Target Prediction for an Open Access Set of Compounds Active against Mycobacterium tuberculosis

Author

Sali, Andrej, Martínez-Jiménez, F, Papadatos, G, Yang, L, Wallace, IM, Kumar, V, Pieper, U, Brown, JR, Overington, JP, and Marti-Renom, MA

Abstract

Mycobacterium tuberculosis, the causative agent of tuberculosis (TB), infects an estimated two billion people worldwide and is the leading cause of mortality due to infectious disease. The development of new anti-TB therapeutics is required, because of the

Published
2013

50. Bacteriophage targeting of gut bacterium attenuates alcoholic liver disease

Author

Duan, Yi, Llorente, Cristina, Lang, Sonja, Brandl, Katharina, Chu, Huikuan, Jiang, Lu, White, Richard C., Clarke, Thomas H., Nguyen, Kevin, Torralba, Manolito, Shao, Yan, Liu, Jinyuan, Hernandez-Morales, Adriana, Lessor, Lauren, Rahman, Imran R., Miyamoto, Yukiko, Ly, Melissa, Gao, Bei, Sun, Weizhong, Kiesel, Roman, Hutmacher, Felix, Lee, Suhan, Ventura-Cots, Meritxell, Bosques-Padilla, Francisco, Verna, Elizabeth C., Abraldes, Juan G., Brown, Jr, Robert S., Vargas, Victor, Altamirano, Jose, Caballería, Juan, Shawcross, Debbie L., Ho, Samuel B., Louvet, Alexandre, Lucey, Michael R., Mathurin, Philippe, Garcia-Tsao, Guadalupe, Bataller, Ramon, Tu, Xin M., Eckmann, Lars, van der Donk, Wilfred A., Young, Ry, Lawley, Trevor D., Stärkel, Peter, Pride, David, Fouts, Derrick E., and Schnabl, Bernd

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results